TEDCO’s Dr. Arti Santhanam: Bringing New Innovations to Market TEDCO Drives Tech Commercialization Among University PartnersI95 BUSINESSBy Kristi S. HalfordApr 13, 2021Technology | Venture Capital + Angel Investors | Medical Innovation In 2012 when [….]
TEDCO, Maryland’s economic engine for technology companies, announced today the appointment of Jack Miner as the chief investment officer. He begins his tenure with TEDCO on March 1, 2021.
5 Questions with Dr. Amritha Jaishankar, Director, Programs and Strategic Alliances, Maryland Stem Cell Research Fund (MSCRF)
Dr. Amritha Jaishankar serves as the Director, Programs and Strategic Alliances, Maryland Stem Cell Research Fund (MSCRF). In this role, Amritha is responsible for oversight of programs, scientific management, and oversight of the portfolio, as well as MSCRF business development. She works with stem cell scientists across Maryland to develop a collaborative research program and promote commercialization of stem cell technologies.
2020 brought about a lot of growth across the BioHealth Capital Region (BHCR) as dozens of organizations responded with urgency to address the COVID-19 pandemic.
In 2020 we introduced a new series titled “5 Questions With…” in an effort to spotlight individuals from across the BioHealth Capital Region and beyond. Providing this platform has allowed us to help share the stories of industry peers and show that there isn’t a single “right” way to becoming an industry success.
Today, we are excited to announce the winners of our inaugural BioBuzz Awards. The BioBuzz Awards are a celebration of the exciting and groundbreaking work being done by the BioHealth Capital Region (BHCR) life science community and the individuals that make innovation happen across Maryland, Virginia, and Washington, D.C.
TEDCO CEO Troy LeMaile-Stovall believes the growth of the life sciences ecosystem in Maryland requires a greater sense of cohesion.
This year, more than ever before, we’ve seen just how important it is for us all to stay connected and work together to build a stronger biotech ecosystem. In the face of great adversity, the biotech community has risen to the challenge and formed new collaborations and partnerships to innovate and rapidly develop new medicines and tools to help us beat this pandemic.
COVID-19 has created significant challenges for the Venture Capital (VC) market and life science companies seeking funding during the pandemic. While the pandemic has undoubtedly added a new layer of risk to an inherently risky field, the fundamentals for what makes a company attractive to a VC have remained steady.
At Maryland Lifesciences’ 2020 Bio Innovation Conference, American Gene Technologies (AGT) took center stage. AGT was the virtual event’s diamond sponsor, AGT’s CEO and Founder Jeff Galvin kicked off the event with opening remarks and then hosted several panel discussions, including “Expanding Progress and Opportunities in Gene and Cell Therapy,” which was a highlight of the conference’s second day.